|
|
|
|
|
|
|
|
Formed in 2007, biOasis is a Vancouver-based biopharmaceutical company engaged in the development and commercialization of technologies for the diagnosis and treatment of central nervous system (“CNS”) diseases & disorders. The World Health Organization declared that CNS disorders represent the major medical challenge of the 21st Century. Valued at more than US $98 billion, the CNS market segment is the 2nd largest category in the pharmaceutical industry and is growing at approximately 8% per annum. Despite the large and growing market, most CNS diseases are difficult or impossible to treat due to the blood-brain barrier (“BBB”). The BBB protects the brain by preventing almost all foreign substances from entering. As a result over 95% of known drugs do not cross the BBB. biOasis is currently focused on two commercialization programs that exploit the physiological and biochemical properties of proteins & peptides that are able to cross the BBB.
biOasis is a publically traded company that trades on the TSX-Venture exchange under the symbol BTI. |
|
|
|
| |
|
|
|
| © 2010 bIOasis Technologies Inc. All Rights Reserved
|
|